Archive · 17 Jun 2025
CAR T-Cell Therapy Shows Promise in Early Solid Tumor Trials
CAR T-cell therapy is a treatment that uses your own immune cells to fight cancer.
It's shown success in blood cancers, and now it's being tried on solid tumors.
Recent studies show improvements in treating stomach and brain cancers.
The therapy involves modifying immune cells to target cancer cells.
However, it's more difficult to treat solid tumors because the cancer cells can be hard to reach.
Researchers are using AI to help find targets.
CAR T-cell therapy, which re-engineers immune cells to fight cancer, is showing promise for solid tumors.
A phase II trial in China showed improved outcomes for gastrointestinal cancer patients using CAR T-cell therapy.
A US study showed positive results with a double-target CAR T-cell therapy for glioblastoma.
Researchers are using AI to find suitable targets, and Indian companies are also developing CAR T-cell therapies.
Challenges remain due to the difficulty in targeting solid cancers and the tumor microenvironment.
- Who
- Researchers and patients with gastrointestinal cancers and glioblastoma are involved.
- What
- CAR T-cell therapy shows early promise in treating solid tumors.
- When
- Recent studies have been published.
- Where
- Studies were conducted in China and the US, with Indian companies also working on therapies.
- Why
- To find effective treatments for solid tumors.
Optimism
Challenges
Potential for Solid Tumors
Optimism
CAR T-cell therapy shows early success in treating solid tumors.
Challenges
Challenges remain due to the difficulty in targeting solid cancers and the tumor microenvironment
- Therapy Type
- CAR T-cell therapy
- Focus
- Solid tumors
- Trial Results (China)
- 35% response rate in gastrointestinal cancer patients
- Trial Results (US)
- Tumor reduction in nearly two-thirds of glioblastoma patients
- Gastrointestinal Cancer Study
- Patients lived 2.4 months longer on average with the new therapy
- Current Research
- Gliomas and CLDN18.2 are in advanced stages